Net Cash Provided by (Used in) Financing Activities in USD of Entero Therapeutics, Inc. from 2015 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Entero Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2015 to Q1 2025.
  • Entero Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2025 was $700K, a 79.3% decline year-over-year.
  • Entero Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $5.58M, a 63.3% decline from 2023.
  • Entero Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $15.2M, a 3.26% decline from 2022.
  • Entero Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $15.7M, a 64.8% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)

Entero Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $700K -$2.68M -79.3% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-15
Q1 2024 $3.38M -$168K -4.74% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-15
Q1 2023 $3.55M -$1.82M -33.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q1 2022 $5.37M -$5.68M -51.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q1 2021 $11.1M +$8.29M +301% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-23
Q1 2020 $2.76M +$789K +40.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-24
Q1 2019 $1.97M -$279K -12.4% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q1 2018 $2.25M +$2.32M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
Q1 2017 -$77.3K -$302K -134% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-14
Q1 2016 $225K Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-15

Entero Therapeutics, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $5.58M -$9.65M -63.3% Jan 1, 2024 Dec 31, 2024 10-K/A 2025-04-09
2023 $15.2M -$513K -3.26% Jan 1, 2023 Dec 31, 2023 10-K/A 2025-04-09
2022 $15.7M -$29M -64.8% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-29
2021 $44.8M +$27.7M +163% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-20
2020 $17M +$3.9M +29.7% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-31
2019 $13.1M +$1.43M +12.2% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-31
2018 $11.7M +$5.7M +94.8% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-30
2017 $6.01M +$267K +4.65% Jan 1, 2017 Dec 31, 2017 10-K 2019-04-01
2016 $5.75M +$1.07M +22.8% Jan 1, 2016 Dec 31, 2016 10-K 2018-03-16
2015 $4.68M Jan 1, 2015 Dec 31, 2015 10-K 2017-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.